Name: Ceftobiprole Medocaril Sodium
Price: 625.00 USD

- Overview
  - Ceftobiprole Medocaril Sodium is the prodrug that is rapidly converted in vivo to Ceftobiprole, its active form by type A plasma esterases. Ceftobiprole is a a broad-spectrum, beta-lactam, fifth-generation Cephalosporin. It has a high binding affinity for penicillin binding proteins in many Gram-positive and Gram-negative bacteria.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. Ceftobiprole Medocaril Sodium has a high affinity for PBP2a conferrring methicillin-resistance in S. aureus, PBP2x conferring penicillin-resistance in S. pneumoniae, and PBP5 in Enterococcus faecalis.
- Properties
  - CAS Number
    
    252188-71-9
    
    Molecular Formula
    
    C26H26N8O11S2 ∙ Na
    
    Molecular Weight
    
    713.65
    
    Appearance
    
    light yellow powder
    
    Solubility
    
    Soluble in water. Slightly soluble in DMSO.
    
    Other Properties
    
    Source: Synthetic
    Purity Level: ≥95% (consult C of A when avail)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Broad-range against Gram-positive and Gram-negative bacteria. It is active in vitro against S. aureus (most MRSA), vancomycin-intrmediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA). S. pneumoniae, and Enterobacteriaceae. It is not active against anaerobic bacteria.
    
    Microbiology Applications: Ceftobiprole Medocaril Sodium has activity against Streptococcus pneumoniae, Enterococcus faecalis. H. influenzae, and P aeruginosa. Resistance among Staphyloccus and streptococcus is uncommon. However, resistance in Enterobacteriaceae is conferred by B-lactamases.